

## Stephen John Haslam Ashcroft Minkowski Award, 1979, Vienna



Stephen Ashcroft was born in 1942. He obtained a Ph. D. in 1969 from the University of Bristol and an M. A. in 1976 from the University of Cambridge, UK. Dr. Ashcroft was at the Department of Biochemistry at the University of Bristol from 1965 to 1975 where he was successively: Research Assistant, Research Associate and Lecturer in Biochemistry. From 1975 to 1990 he became a Lecturer in Clinical Biochemistry at the University of Oxford and a Tutor in Biochemistry at Magdalen College Oxford. Since 1990 Dr. Ashcroft has been a Reader in Clinical Biochemistry at the University of Oxford. Dr. Ashcroft's current research activities concern molecular characterisation of the ATP-sensitive K-channel in pancreatic beta cells; the role of protein phosphorylation in the regulation of insulin secretion; regulation of insulin gene expression.

## **Protein phosphorylation and beta-cell function**

## S.J.H. Ashcroft

Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford, UK

**Summary** The central role of reversible protein phosphorylation in regulation of beta-cell function is reviewed and the properties of the protein kinases so far defined in beta cells are summarised. The key effect of Ca<sup>2+</sup> to initiate insulin secretion involves activation of a Ca<sup>2+</sup>/calmodulin-dependent protein kinase. Potentiation of secretion by agents activating protein kinase A or C appears to involve an increase in the sensitivity of the secretory system to intracellular Ca<sup>2+</sup>. The effects of MgATP on the binding of <sup>3</sup>H]-glibenclamide to the beta-cell sulphonylurea receptor suggest that the properties of this receptor, which controls the activity of ATP-sensitive K-channels, are modulated by phosphorylation. The identity of the kinases and phosphatases responsible is not known but the presence in beta-cell membranes of various kinases not dependent on Ca<sup>2+</sup> or cyclic AMP, and including tyrosine kinase, is documented, together with the presence of both Ca<sup>2+</sup>-dependent

and  $Ca^{2+}$ -independent protein phosphatases. Protein phosphorylation is also involved in regulation of beta-cell  $Ca^{2+}$  fluxes and evidence is presented that protein kinase C activation inhibits  $Ca^{2+}$  signalling by reducing influx of  $Ca^{2+}$  into the beta cell. The identity of the  $Ca^{2+}/calmodulin-dependent$  protein kinase activity in beta cells is discussed. Comparison of its properties towards substrates and inhibitors with those of brain  $Ca^{2+}/calmodulin-dependent$  protein kinase II suggests that the beta-cell enzyme may be similar or identical to the brain enzyme. Evidence from Northern and Western blotting experiments supports this conclusion. These findings are incorporated in a model for control of insulin secretion. [Diabetologia (1994) 37 [Suppl 2]: S21–S29

**Key words** Protein kinase, phosphorylation, protein phosphatase, beta cell, insulin secretion, sulphonylurea receptor.

*Corresponding author:* Dr. S.J.H. Ashcroft, Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK

Abbreviations: K-ATP channels; ATP-sensitive potassium channels; DAG, diacylglycerol; TPA, 12-O-tetradecanoyl phorbol acetate; CaM kinase, calcium/calmodulin-dependent protein kinase.

In the beta cell, reversible protein phosphorylation is implicated in the control of insulin secretion and probably also in insulin biosynthesis. However, the important goal of elucidating which of the 'one thousand and one protein kinases' [1] and 'one thousand and two protein phosphatases' [2] are involved in these functions is far from easy. Approaches taken include i) detection and characterisation of specific protein kinases in the beta cell; ii) determination of the effects of activators and inhibitors of protein kinases on insulin secretion; iii) detection and identification of specific phosphoproteins whose phosphorylation state varies with changes in rates of secretion. In this paper I shall first briefly survey the main conclusions that have been drawn from these studies and then focus on selected areas of our current research.

### **Beta-cell protein kinases**

## Protein kinase A

Protein kinase A has been partially purified from rat pancreatic islets and shown to comprise two isoenzymes corresponding to the 'Type I' and 'Type II' holoenzymes found in other tissues [3]. The two isoenzymes differ in their ease of dissociation by histone or NaCl and as in other tissues are likely to share the same catalytic subunit. An M<sub>r</sub> of 144,200 was calculated from measurements of sedimentation coefficient and Stokes' radius [3]. Studies with subcellular fractions or intact islets (reviewed in detail in [4]) have demonstrated the existence in beta cells of numerous substrates for protein kinase A, several of which have been identified by more than one laboratory using different procedures. At the present time, however, the nature of the endogenous substrates and their relationship to the secretory process have not been defined.

Although it is well established that glucose elicits a modest increase in beta-cell cyclic AMP [5–8] the mechanism by which this occurs has not been established. Moreover, there is strong evidence that activation of protein kinase A is not necessary for glucoseinduced insulin release [9]. The role of cyclic AMPdependent protein phosphorylation is therefore to mediate the potentiatory effects on glucose-induced insulin release elicited by glucagon, gastric inhibitory peptide or glucagon-like polypeptide- $1_{7-36}$ amide [10].

## Protein kinase C

Protein kinase C has been purified to homogeneity from beta cells and shown to be a monomer of  $M_r$  85,200 [11]. The predominant isoform expressed in

beta cells of adult islets of Langerhans is protein kinase C- $\alpha$  [12–14]. The presence of other isoforms can be demonstrated by polymerase chain reaction or Northern blotting [15]. Endogenous substrates for protein kinase C can be demonstrated in beta cells [16–18]. Inhibition of protein kinase C by clomiphene has been correlated with changes in phosphorylation of a 37 kDa particulate protein in islets of Langerhans and inhibition of insulin secretion [19]. However, with the exception of MARCKS (myristoylated alanine-rich C-kinase substrate [20]) the identity of the endogenous beta-cell substrates for protein kinase C is unknown and their role in secretion has not been established.

Whether protein kinase C activation is involved in glucose-stimulated insulin release has been controversial (for review see [21]). There is evidence that activation of protein kinase C occurs in islets in response to an increase in glucose concentration [20]. However, it is doubtful whether this increase in activity is of major importance for secretion since most studies find that glucose-induced insulin release is little affected by down-regulation of protein kinase [22–24]. The main role of protein kinase C in insulin secretion may therefore be to mediate the potentiatory effects of agents such as acetylcholine and chole-cystokinin which activate phospholipase C and hence increase the beta-cell level of diacylglycerol and  $IP_3$  [10].

## Calcium/calmodulin-dependent protein kinases

The beta cell contains a high concentration of calmodulin [25] and inhibitors of calmodulin block insulin secretion [26]. The existence of several betacell calcium/calmodulin-dependent protein kinases has been demonstrated. Myosin light chain kinase is present in beta cells [27] and could potentially play a role in granule movement – however, there is no direct evidence for such a mechanism. Calcium/calmodulin-dependent phosphorylation of a peptide of M. approximately 53 kDa has been widely reported in beta cells [28–30]. Although various suggestions have been made as to the identity of the 53 kDa species, including pyruvate kinase [31] and tubulin [32], it seems most likely to represent autophosphorylation of a kinase (P53 kinase). Since inhibition of P53 kinase by alloxan [33] or dehydrouramil [34] was found to be associated with inhibition of insulin release, a central role for P53 kinase in initiation of insulin secretion has been proposed [29]. The identity of P53 kinase is considered below.



#### Fig.1. Protein phosphorylation and insulin secretion. Initiation of insulin secretion by glucose or sulphonylureas involves closure of K-ATP channels and an influx of Ca<sup>2+</sup> via L-type Ca<sup>2+</sup> channels. Ca2+/calmodulin-dependent protein kinase II (CaMK II) is suggested to play a key role in mediating the initiation of insulin secretion by Ca2+. Hormones and neurotransmitters have multiple sites of action on the beta cell. Potentiation of secretion (stippled arrows) occurs when protein kinases A or C are activated by cyclic AMP or DAG, respectively. These second messengers are formed in response to activation of adenyl cyclase (AC) or phospholipase C (PLC) by occupation of receptors linked to $G_s$ or $G_q$ . Activation of PLC also liberates IP3 which releases Ca2+ from intracellular stores. Adenycl cyclase can be inhibited by occupation of receptors coupled to Gi. However, inhibitory effects on secretion are also exerted via opening of K-channels and effects on the secretory process itself, both probably involving further G-proteins. Inhibitory effects are indicated by the filled arrows and stimulatory effects by the open arrows

# Protein phosphorylation and the beta-cell sulphonylurea receptor

The potency of sulphonylureas in stimulating insulin release parallels their ability to close K-ATP channels in the beta-cell plasma membrane (for review see [35]). Closure of K-ATP channels leads to membrane depolarisation and the resulting influx of Ca<sup>2+</sup> ions through voltage-dependent Ca<sup>2+</sup> channels triggers insulin secretion (reviewed in [36]). Glucose, the major physiological regulator of insulin secretion, closes K-ATP channels because increased plasma glucose concentrations cause increased rates of metabolism of the sugar within the beta cell; the resultant increase in intracellular [ATP]/[ADP] blocks K-ATP channel activity. Sulphonylureas, however, close K-ATP channels by directly binding to high affinity sites within the beta-cell membrane. It is currently unclear whether the sulphonylurea-binding sites are identical to the K-ATP channels or whether they are a distinct protein which modulates channel activity.

An inhibitory effect of MgATP has been observed on sulphonylurea binding to beta-cell membranes [37–39]. The nucleotide specificity and requirement for Mg<sup>2+</sup> of this inhibitory effect of ATP suggested that protein phosphorylation could modulate the properties of the sulphonylurea receptor [38, 39]. This interpretation is supported by the finding that the effect of MgATP on the K<sub>d</sub> for binding of [<sup>3</sup>H]glibenclamide to mouse islet membranes is not in accordance with a competitive interaction of glibenclamide and MgATP [38].

Since diazoxide inhibits insulin secretion by opening K-ATP channels in pancreatic beta cells [40], it is likely that this sulphonamide also interacts with the sulphonylurea receptor. However, we found that diazoxide, alone, failed to influence [<sup>3</sup>H]-glibenclamide binding to membranes from HIT T15 beta cells [37]. On the other hand, diazoxide did inhibit [<sup>3</sup>H]glibenclamide binding to whole HIT cells and the magnitude of this effect was decreased when the cells were depleted of ATP [37]. Direct evidence that ATP could influence the binding of diazoxide to the sulphonylurea receptor was obtained by showing that diazoxide was able to displace [<sup>3</sup>H]-glibenclamide from HIT beta-cell [37] or islet [39] membranes in the presence of MgATP. This effect of MgATP was not reproduced by non-metabolizable ATP analogues or by ATP in the absence of  $Mg^{2+}$ . In the presence of 1 mmol/l-MgATP, diazoxide inhibited [<sup>3</sup>H]-glibenclamide binding to HIT cell membranes over the same range of diazoxide concentrations that increased <sup>86</sup>Rb efflux from HIT cells [37, 41]. These results suggest that protein phosphorylation can modulate the binding to the sulphonylurea receptor not only of glibenclamide but also of diazoxide.

There are several possible explanations for the modulation by phosphorylation of the effect of diazoxide on [<sup>3</sup>H]-glibenclamide binding. Firstly, diazoxide may activate a kinase which phosphorylates the sulphonylurea receptor/K-ATP channel. We consider that this is unlikely, since we find that diazoxide retains the ability to inhibit binding to membranes exposed to MgATP even when added after the added ATP has been hydrolysed by endogenous ATPase activity. Furthermore, we find no effect of diazoxide on incorporation of <sup>32</sup>P from  $[\gamma$ -<sup>32</sup>P]-ATP into HIT-cell membrane proteins. Secondly, diazoxide may inhibit a protein phosphatase which dephosphorylates the glibenclamide receptor/K-ATP channel. This also seems unlikely, since diazoxide inhibits [3H]-glibenclamide binding even in the presence of NaF, an inhibitor of protein phosphatases. Moreover, we find no effect of diazoxide on dephosphorylation of HIT-cell membrane proteins labelled by incubation with  $\gamma$ -<sup>32</sup>P]-ATP. We therefore conclude that diazoxide may directly inhibit [<sup>3</sup>H]-glibenclamide binding to the receptor by itself binding to the phosphorylated receptor or a related protein(s).

Three findings suggest that the phosphorylation of the receptor necessary for diazoxide to inhibit [<sup>3</sup>H]glibenclamide binding may occur at two different sites. Firstly, the time course for inhibition of [<sup>3</sup>H]glibenclamide binding by MgATP differs from that for inhibition by diazoxide in the presence of MgATP. Secondly, ATP- $\gamma$ S has only a small inhibitory effect on binding but permits sustained inhibition by diazoxide. Thirdly, although inhibition of [<sup>3</sup>H]-glibenclamide binding by MgATP can also be observed for the solubilised receptor, we do not see the revealing effect of MgATP on diazoxide-evoked inhibition of glibenclamide binding to the solubilised receptor, suggesting that the inhibitory and revealing effects of MgATP are mediated by distinct pathways.

These findings require that beta-cell membranes contain both protein kinase(s) and protein phosphatase(s) active under the conditions of our binding assays. Since the latter are conducted in the absence of added Ca<sup>2+</sup> or cyclic AMP the protein kinases are presumably distinct from those discussed above. We have begun to characterise these activities. When HIT T15 beta-cell membranes were incubated with  $[\gamma^{-32}P]$ -ATP there was substantial incorporation of <sup>32</sup>P into membrane proteins. Phosphorylation was maximal after 5 min and declined thereafter. Since exogenous kinases were not added to the incubation buffer, these data indicate the presence of endogenous kinases in HIT beta-cell membranes. Furthermore, since the incubation medium contained 0.25 mmol/l-EGTA, it appears that the kinase(s) involved are not strongly Ca<sup>2+</sup>-dependent.

The decline in phosphorylation is indicative of endogenous phosphatase activity; after 5 min, the  $[\gamma^{-32}P]$ -ATP in the incubation mixture was completely hydrolysed by endogenous ATPase activity and rephosphorylation could therefore not occur. Since dephosphorylation occurs in the absence of Ca<sup>2+</sup>, the phosphatases involved also do not have a high Ca<sup>2+</sup>requirement.

In the absence of  $Mg^{2+}$ , most of the incorporation of radioactivity was not evident, confirming that it re-

sults from protein phosphorylation. In the absence of Mg<sup>2+</sup>, a protein of molecular weight 45 kDa was strongly labelled and there was weak labelling of a 120 kDa band; in the additional presence of 2 mmol/ 1-EDTA, the latter band was shifted to 115 kDa. We used  $[\alpha^{-32}P]$ -ATP to investigate whether these proteins were labelled with <sup>32</sup>P by phosphorylation or by some other mechanism which involved covalent incorporation of <sup>32</sup>P-ATP. After incubation with  $\left[\alpha\right]$ <sup>32</sup>P]-ATP in the presence of Mg<sup>2+</sup>, radioactivity was found in an 80 kDa band. The intensity of this band was reduced in Mg<sup>2+</sup>-free solution and was absent in the additional presence of 2 mmol/l-EDTA, suggesting that the 80 kDa protein is covalently labelled by MgATP but not by free ATP. In the presence of EDTA and EGTA, label was incorporated into an additional 135 kDa band, suggesting that this protein is covalently labelled by free ATP. This 135 kDa protein may correspond to the 120/115 kDa band found with  $[\gamma^{-32}P]$ -ATP in Mg<sup>2+</sup>-free solution consistent with labelling of this protein by <sup>32</sup>P-ATP and not by <sup>32</sup>P-phosphate. No label was found in a 45 kDa protein with  $[\alpha^{-32}P]$ -ATP. This result suggests that the 45 kDa protein, labelled after incubation in Mg<sup>2+</sup>free solution with  $[\gamma^{-32}P]$ -ATP, is labelled with  ${}^{32}P$ phosphate and not with [<sup>32</sup>P]-ATP. This result may indicate Mg<sup>2+</sup>-independent phosphorylation of the 45 kDa protein.

We also examined the effects of protein kinase inhibitors on the incorporation of  $[\gamma^{-32}P]$  into HIT beta-cell membranes. Protein kinase A inhibitor peptide  $(10 \,\mu mol/l)$  slightly reduced labelling of a 100 kDa band but was without effect on most labelled species. Protein kinase C inhibitor peptide  $(10 \,\mu mol/l)$ without was effect. Tyrphostin (100 µmol/l), an inhibitor of tyrosine kinases, almost completely abolished phosphorylation of an 80 kDa band and decreased labelling of bands at 115 and 68 kDa. These results suggest that protein kinase A and tyrosine kinase activity are present in HIT-cell membranes but that substrate proteins are few.

The effects on dephosphorylation of HIT beta-cell membranes of a number of agents known to inhibit or activate protein phosphatases were also studied. In these experiments, membranes were first phosphorylated for 5 min. A sample was removed and the membranes incubated for a further 30 min in the presence or absence of various inhibitors or activators. The non-specific phosphatase inhibitors NaF and  $Na_3VO_4$  had marked effects on dephosphorylation of HIT beta-cell membrane proteins. NaF caused marked preservation of label in several proteins, particularly those of 45, 50, 54 and 57 kDa. Na<sub>3</sub>VO<sub>4</sub> also strongly decreased dephosphorylation of the proteins affected by NaF. In addition, it is of interest that phosphorylation of a 115 kDa species, whose phosphorylation was reduced by tyrphostin, was markedly and specifically enhanced by 1 mmol/l $Na_3VO_4$ , which, at this concentration, inhibits phosphotyrosine phosphatases. This observation provides further evidence that the 115 kDa substrate protein is phosphorylated on tyrosine residues.

Microcystin produced a dose-dependent inhibition of dephosphorylation of 45, 50, 54, 60, 68 and 135 kDa bands, suggesting the presence of membrane-bound protein phosphatases 1 and/or 2A; the 115 kDa protein was unaffected. Addition of 5 mmol/l-CaCl<sub>2</sub> markedly potentiated dephosphorylation of a 45 kDa protein suggesting the additional presence of an endogenous Ca<sup>2+</sup>-dependent phosphatase; dephosphorylation of most bands was not affected by calcium.

These observations indicate that beta-cell membrane fractions contain numerous protein kinase and phosphatase activities potentially capable of modifying K-ATP channel activity and other beta-cell membrane functions. There is evidence from secretion studies that tyrosine kinase activities may have functional importance for the beta cell [42, 43].

## Protein kinase C, $Ca^{2+}$ and insulin secretion

Acetylcholine causes a sustained potentiation of glucose-stimulated insulin release [24]. The effect is mediated by M<sub>2</sub>-muscarinic receptors [44] coupled to phospholipase C which generates an increase in DAG and IP<sub>3</sub>. The former will activate protein kinase C while the latter can evoke mobilisation of Ca<sup>2+</sup> from intracellular stores. However, we find that the transient increase in intracellular Ca<sup>2+</sup> induced by acetylcholine is prevented in the absence of extracellular Ca2+ or when influx of Ca2+ is blocked by verapamil [24]. Hence  $Ca^{2+}$  entry, rather than  $Ca^{2+}$ mobilisation, may be the main contributor to the acetylcholine-evoked increase in intracellular  $Ca^{2+}$ . This increase is, however, relatively modest and transient. Therefore, the activation of protein kinase C by DAG may be of more importance for the increase in insulin release. We have examined this possibility further by examining the effects of inhibition or down-regulation of protein kinase C on potentiation of insulin release by acetylcholine [24]. HIT T15 beta cells were exposed to a phorbol ester, TPA, for 24 h which resulted in a 73 % decrease in the activity of protein kinase C. Down-regulation of protein kinase C had no significant effect on either the sustained rise induced by glucose or the transient increase in intracellular [Ca2+] induced by acetylcholine. However, insulin release was markedly affected by pretreatment with TPA; the secretory response to glucose was somewhat reduced and the potentiation by acetylcholine completely abolished. In contrast the potentiation induced by activating protein kinase A by the addition of forskolin was not reduced by preexposure to TPA. These findings suggest that acetylcholine potentiates insulin secretion by a two-step mechanism. An initial increase in intracellular  $Ca^{2+}$ as a consequence of enhanced influx through voltage-dependent  $Ca^{2+}$  channels stimulates insulin release and primes the secretory mechanism for protein kinase C activation; this in turn sensitises the secretory mechanism to  $Ca^{2+}$ , causing sustained insulin release.

The above studies provided no evidence for a stimulatory effect of protein kinase C on intracellular  $Ca^{2+}$ . Further studies have shown that protein kinase C activation is actually associated with a *lowering* of intracellular Ca<sup>2+</sup>. In a first series of experiments we subjected HIT T15 beta cells to step-wise increases in extracellular  $Ca^{2+}$  [45]. In the presence of a stimulatory concentration of glucose, this resulted in stepwise increases in intracellular Ca<sup>2+</sup>. TPA had no effect on intracellular Ca<sup>2+</sup> in the absence of glucose but, in the presence of 10 mmol/l glucose, TPA lowered the intracellular Ca<sup>2+</sup> by around 20% at all extracellular Ca2+ concentrations greater than 0.25 mmol/l. Despite lowering intracellular Ca<sup>2+</sup>, TPA potentiated insulin secretion at all extracellular  $Ca^{2+}$  concentrations tested. It was also noted that TPA lowered the threshold extracellular Ca<sup>2+</sup> concentration at which glucose stimulated insulin release.

In a second series of experiments [46] we studied the effects of vasopressin. Vasopressin was shown to elicit marked insulin release from HIT T15 beta cells. As for acetylcholine this stimulation was dependent on the presence in the extracellular medium of both glucose and Ca<sup>2+</sup>. Vasopressin also evoked a marked, concentration-dependent increase in intracellular  $Ca^{2+}$  which was biphasic – an initial spike was followed by a sustained elevation. This increase also required glucose and was blocked in the absence of extracellular Ca<sup>2+</sup> or presence of verapamil. Down-regulation of protein kinase C had no effect on the vasopressin-induced increases in insulin or Ca<sup>2+</sup> indicating that protein kinase C has no direct role in vasopressin-induced insulin release. However, short-term exposure to TPA markedly reduced the steady-state level of Ca<sup>2+</sup> attained in the presence of 2 mmol/l glucose and totally abolished the rise in intracellular Ca<sup>2+</sup> elicited by vasopressin. Evidence that this effect of TPA was indeed mediated by protein kinase C was provided by the observations that the inhibitory action could be prevented both by down-regulation of protein kinase C or by inhibition of protein kinase C with staurosporine. Short-term exposure to TPA did not, however, inhibit vasopressin-induced insulin release. These findings suggest that protein kinase C activation inhibits  $Ca^{2+}$  signalling by reducing influx of  $Ca^{2+}$  into the beta cell. Despite this effect on intracellular Ca<sup>2+</sup>, which has also been observed in mouse islets [47], insulin secretion is enhanced by activation of protein kinase C. We interpret this as indicating that protein kinase C activation stimulates insulin release primarily by sensitising the beta-cell secretory system to  $Ca^{2+}$ .

# Calcium/calmodulin-dependent protein kinase II in the beta cell

In several respects, the beta-cell CaM kinase that phosphorylates an endogenous beta-cell protein of M<sub>r</sub> 53 kDa resembles CaM kinase II, a multifunctional CaM kinase. CaM kinase II (for review see [48]) is an oligomeric protein of M<sub>r</sub> around 500–600 kDa, composed of distinct but related subunits of 50 to 60 kDa in various ratios. The enzyme is widely distributed and shows a broad substrate specificity. Both the  $\alpha$  and  $\beta$  subunits can be autophosphorylated in a Ca<sup>2+</sup>/calmodulin-dependent manner resulting in the appearance of Ca<sup>2+</sup>-independent kinase activity. The cDNAs for both  $\alpha$  and  $\beta$  subunits have been cloned and the deduced amino acid sequences described [49-50]. These subunits are highly homologous. Further homologous subunits ( $\beta$ ',  $\gamma$  and  $\delta$ ) have also been identified by molecular cloning [51]. A major substrate for CaM kinase II in nerve tissue is synapsin I which is bound to a high affinity site on synaptic vesicles [52] and may link the vesicles to the cytoskeleton [53]. Phosphorylation of synapsin I by CaM kinase II reduces the affinity of this interaction [54] and a role for this phosphorylation in neurotransmitter release postulated [55]. Direct evidence for this came from experiments on isolated nerve terminals. When CaM kinase was activated by thiophosphorylation and introduced into rat brain synaptosomes, enhanced rates of release of glutamate and noradrenalin were observed together with increased phosphorylation of synapsin I [56]. Further evidence was obtained by introducing a specific peptide inhibitor of CaM kinase into synaptosomes; the rate of glutamate release was significantly inhibited.

In view of the  $M_r$  of the beta-cell CaM kinase, its aggregation under non-denaturing conditions, its association with the cytoskeleton and its autophosphorylation we have investigated the possibility that the beta-cell enzyme may be CaM kinase II.

It has been shown that CaM kinase activity in homogenates of brain and islets is susceptible to inhibition by alloxan [33]. We showed that dehydrouramil, an analogue of alloxan, also inhibits beta-cell CaM kinase at concentrations of dehydrouramil that produced a marked inhibition of insulin release [34]. We then compared the substrate specificity of CaM kinase activity in extracts of islets with purified brain CaM kinase II [57]. Islet CaM kinase phosphorylated major endogenous substrates of 102, 57 and 53 kDa and also exogenous glycogen synthase: brain CaM kinase II phosphorylated glycogen synthase and peptides of 57 and 53 kDa. Alloxan (1 mmol/l) inhibited the phosphorylation of glycogen synthase and the 102, 57 and 53 kDa islet peptides by islet CaM kinase; the phosphorylation of glycogen synthase and the 57 and 53 kDa substrates by brain CaM kinase II was also inhibited by alloxan. The 102 kDa substrate was located in the post-100,000 g supernatant and the 57 and 53 kDa substrates in a particulate fraction. These data suggest that islet CaM kinase II.

We have now obtained direct evidence that beta cells contain CaM kinase II from Northern and Western blotting [58]. Northern blots of RINm5F beta cells with a riboprobe for brain CaM kinase II  $\alpha$ -subunit reveal a single band of 4500 bp. We also find, in agreement with [59], that antibodies to a peptide corresponding to residues 281–309 of brain CaM kinase II detect a band of approximately 50 kDa on Western blots of islets that corresponds to a peak of Ca<sup>2+</sup>/calmodulin-dependent phosphorylation.

Evidence for involvement of CaM kinase in insulin secretion is provided by the demonstration that loss of Ca<sup>2+</sup>-induced insulin release from permeabilised islets is accompanied by loss of Ca2+-induced protein phosphorylation [60]. Inhibition of glucose-stimulated insulin release by the CaM kinase II inhibitor KN-62 [61] is consistent with a role for the kinase in glucose-induced insulin release. However, this finding is not conclusive since KN-62 may also have a direct effect on L-type Ca-channels in beta cells [62]. Stronger evidence that CaM kinase II mediates the stimulatory effect of glucose on insulin secretion has come from the demonstration that exposure to increased glucose concentrations increased the extent of autophosphorylation of islet CaM kinase II detected by immunoprecipitation [63]. That inhibition of beta-cell CaM kinase results in inhibition of insulin secretion has also been shown at the single cell level by the patch clamp technique [64]. Exocytosis from single beta cells was followed by measuring the capacitance of the plasma membrane. Capacitance is proportional to surface area which increases when secretory vesicles fuse with the plasma membrane: changes in cell capacitance may thus be used to monitor exocytosis. It was shown that a specific peptide inhibitor of CaM kinase II (residues 290-309) markedly reduced secretion when included in the pipette solution without affecting the Ca<sup>2+</sup> current. Therefore, beta-cell CaM kinase II regulates insulin secretion distal to the elevation of intracellular Ca<sup>2+</sup>.

The different  $Ca^{2+}$  and calmodulin-dependencies of phosphorylation of the endogenous islet substrates suggested that a distinct kinase was involved in phosphorylating the 102 kDa species [57]. This kinase probably corresponds to CaM kinase III and the 102 kDa substrate to elongation factor 2 since the 102 kDa peptide was shown to undergo ADP- ribosylation in the presence of diphtheria toxin and NAD<sup>+</sup> [57]. A role for CaM kinase III in regulation of insulin biosynthesis thus seems possible.

### Conclusions

Figure 1 depicts a model for control of insulin secretion incorporating some of the findings discussed here. Protein phosphorylation is suggested to play a central role in regulation of beta-cell function with CaM kinase II mediating a key triggering effect of  $Ca^{2+}$  on secretion. Potentiation of secretion by agents activating protein kinase A or C appears to involve an increase in the sensitivity of the secretory system to intracellular  $Ca^{2+}$  [44, 45, 65, 66].

The situation is undoubtedly more complex than shown in this model. Thus, protein kinase A and protein kinase C activation can also modulate beta-cell ion fluxes both positively and negatively [47, 67, 68]. The beta-cell also contain, numerous so far uncharacterised protein kinases. These can be detected in membrane fractions and include tyrosine kinase activity. Interestingly, the tyrosine kinase inhibitor genistein has been shown to block interleukin  $1\beta$ -induced inhibition of insulin secretion and formation of nitric oxide in beta-cells [42]. Tyrosine kinase inhibitors also inhibit glucose-induced insulin release [43]. Arachidonic acid and some other fatty acids activate a beta-cell protein kinase distinct from protein kinase A or C [69]. Extracts of beta cells can also be shown to contain protein phosphatase activities, and in permeabilised islets it has been shown that the protein phosphatase inhibitor okadaic acid enhanced both basal and cyclic AMP-induced insulin secretion and protein phosphorylation [70]. The relevant protein phosphatases have not yet been characterised.

Perhaps the greatest limitation of current knowledge is that the phosphoprotein substrate(s) relevant to secretion have not been defined and exocytosis remains a poorly understood process. Future progress requires molecular characterisation of the components of the secretory machinery.

Acknowledgements. Work from my laboratory has been supported by grants from the Medical Research Council and the British Diabetic Association. The contribution of the following post-doctoral researchers to my group's studies on betacell protein phosphorylation described here is gratefully acknowledged: Mary Sugden, Donna Harrison, Mike Christie, Janet Lord, Steve Hughes, Ichiro Niki, Virginia Urquidi, Frances Ashcroft, Barbara Coles.

### References

- Hunter T (1987) A thousand and one protein kinases. Cell 50: 823–829
- Charbonneau H, Tonks NK (1992) 1002 Protein phosphatases? Annu Rev Cell Biol 8: 463–493

- 3. Sugden MC, Ashcroft SJH, Sugden PH (1979) Protein kinase activities in rat pancreatic islets of Langerhans. Biochem J 180: 219–229
- Hughes SJ, Ashcroft SJH (1991) Cyclic AMP, protein phosphorylation and insulin release. In: Flatt PR (ed) Nutrient regulation of insulin secretion. Portland Press London, pp 271–288
- 5. Grill V, Cerasi E (1973) Activation by glucose of adenyl cyclase in pancreatic islets of the rat. FEBS Lett 33: 311-314
- Charles MA, Lawecki J, Prictel R, Grodsky GM (1975) Insulin secretion. Interrelationships of glucose, cAMP and calcium. J Biol Chem 250: 6134–6140
- Christie MR, Ashcroft SJH (1984) Cyclic AMP-dependent protein phosphorylation and insulin secretion in intact islets of Langerhans. Biochem J 218: 87–99
- Thams P, Capito K, Hedeskov CJ (1988) Stimulation by glucose of cyclic AMP accumulation in mouse pancreatic islets is mediated by protein kinase. Biochem J 253: 229–234
- Persaud SJ, Jones PM, Howell SL (1990) Glucose-stimulated insulin secretion is not dependent on activation of protein kinase A. Biochem Biophys Res Commun 173(3): 833–839
- Berggren P-O, Rorsman P, Efendic S et al. (1992) Mechanisms of action of entero-insular hormones, islet peptides and neural input on the insulin secretory process. In: Flatt PR (ed) Nutrient regulation of insulin secretion. Portland Press, London, pp 289–318
- Lord JM, Ashcroft SJH (1984) Identification and characterization of Ca<sup>2+</sup>-phospholipid-dependent protein kinase in rat islets and hamster B-cells. Biochem J 219: 547–551
- Fletcher DJ, Ways DK (1991) Age-dependent expression of protein kinase C isoforms in rat islets. Diabetes 40: 1496–1503
- Ganesan S, Calle R, Zawalich K, Smallwood JI, Zawalich WS, Rasmussen H (1990) Glucose-induced translocation of protein kinase C in rat pancreatic islets. Proc Natl Acad Sci USA 87: 9893–9897
- 14. Onoda K, Hagiwara M, Hachiya T, Usuda N, Nagata T, Hidaka H (1990) Different expression of protein kinase C isozymes in pancreatic islet cells. Endocrinology 126: 1235–1240
- Selbie LA, Schmitz-Peiffer C, Sheng Y, Biden TJ (1993) Molecular cloning and characterization of PKC<sub>l</sub>, an atypical isoform of protein kinase C derived from insulin-secreting cells. J Biol Chem 268: 24296–24302
- Dunlop ME, Larkins RG (1986) Glucose-induced phospholipid-dependent protein phosphorylation in neonatal rat islets. Arch Biochem Biophys 248: 562–569
- Brocklehurst KW, Hutton JC (1984) Involvement of protein kinase C in the phosphorylation of an insulin granule membrane protein. Biochem J 220: 283–290
- Thams P, Capito K, Hedeskov CJ (1984) Endogenous substrate proteins for Ca<sup>2+</sup>-calmodulin-dependent, Ca<sup>2+</sup>-phospholipid-dependent and cyclic AMP-dependent protein kinases in mouse pancreatic islets. Biochem J 221: 247–253
- Hughes SJ, Ashcroft SJH (1988) Effects of a phorbol ester and clomiphene on protein phosphorylation and insulin secretion in rat pancreatic islets. Biochem J 249: 825–830
- 20. Calle R, Ganesan S, Smallwood JI, Rasmussen H (1992) Glucose-induced phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in isolated rat pancreatic islets. J Biol Chem 267: 18723–18727
- 21. Metz SA (1988) Is protein kinase C required for physiologic insulin release? Diabetes 37: 3–7
- Jones PM, Persaud SJ, Howell SL (1992) Insulin secretion and protein phosphorylation in PKC-depleted islets of Langerhans. Life Sci 50: 761–767

- 23. Hii CST, Jones PM, Persaud SJ, Howell SL (1987) A re-assessment of the role of protein kinase C in glucose-stimulated insulin secretion. Biochem J 246: 489–493
- 24. Hughes SJ, Chalk JG, Ashcroft SJH (1990) The role of cytosolic free Ca<sup>2+</sup> and protein kinase C in acetylcholine-induced insulin release in the clonal beta-cell line, HIT-T15. Biochem J 267: 227–232
- 25. Sugden MC, Christie MR, Ashcroft SJH (1979) Presence and possible role of calcium-dependent regulator (calmodulin) in rat islets of Langerhans. FEBS Letts 105: 95–100
- 26. Gagliardino JJ, Harrison DE, Christie MR, Gagliardino EE, Ashcroft SJH (1980) Evidence for the participation of calmodulin in stimulus-secretion coupling in the pancreatic β-cell. Biochem J 192: 919–927
- MacDonald MJ, Kawluru A (1982) Calcium-calmodulindependent myosin phosphorylation by pancreatic islets. Diabetes 31: 566–570
- Penn EJ, Brocklehurst KW, Sopwith AM, Hales CN, Hutton JC (1982) Ca<sup>2+</sup>-calmodulin dependent myosin lightchain phosphorylating activity in insulin secreting tissues. FEBS Letts 139: 4–8
- 29. Harrison DE, Ashcroft SJH, Christie MR, Lord JM (1984) Protein phosphorylation in the pancreatic β-cell. Experientia 40: 1057–1084
- 30. Harrison DE, Ashcroft SJH (1982) Effects of Ca<sup>2+</sup>, calmodulin and cyclic AMP on the phosphorylation of endogenous proteins by homogenates of rat islets of Langerhans. Biochim Biophys Acta 714: 313–319
- MacDonald MJ, Kawluru A (1985) Evidence for calcium enhanced phosphorylation of pyruvate kinase by pancreatic islets. Mol Cell Biochem 68: 107–114
- 32. Colca JR, Brooks CL, Landt M, McDaniel ML (1983) Correlation of Ca<sup>2+</sup>- and calmodulin-dependent protein kinase activity with secretion of insulin from islets of Langerhans. Biochem J 212: 819–827
- 33. Colca JR, Kotagal N, Brooks C, Lacy PE, Landt M, McDaniel ML (1983) Alloxan inhibition of a Ca<sup>2+</sup> and calmodulin-dependent protein kinase activity in pancreatic islets. J Biol Chem 258: 7260–7263
- 34. Harrison DE, Poje M, Rocic B, Ashcroft SJH (1986) Effects of dehydrouramil of protein phosphorylation and insulin secretion in rat islets of Langerhans. Biochem J 237: 191–196
- Ashcroft SJH, Ashcroft FM (1992) The sulfonylurea receptor. Biochim Biophys Acta Mol Cell Res 1175: 45–59
- Ashcroft SJH, Ashcroft FM (1990) Properties and functions of ATP-sensitive K-channels. Cell Signal 2: 197–214
- 37. Niki I, Ashcroft SJH (1991) Possible involvement of protein phosphorylation in the regulation of the sulphonylurea receptor of a pancreatic beta-cell line, HIT T15. Biochim Biophys Acta Mol Cell Res 1133: 95–101
- Schwanstecher M, Löser S, Brandt C, Scheffer K, Rosenberger F, Panten U (1992) Adenine nucleotide-induced inhibition of binding of sulphonylureas to their receptor in pancreatic islets. Br J Pharmacol 105: 531–534
- 39. Schwanstecher M, Löser S, Rietze I, Panten U (1991) Phosphate and thiophosphate group donating adenine and guanine nucleotides inhibit glibenclamide binding to membranes from pancreatic islets. Naunyn-Schmiedeberg's Arch Pharmcol 343: 83–89
- 40. Trube G, Rorsman P, Ohno-Shosaku T (1986) Opposite effects of tolbutamide and diazoxide on the ATP-dependent K<sup>+</sup> channel in mouse pancreatic beta-cells. Pflugers Arch 407: 493–499
- 41. Niki I, Kelly RP, Ashcroft SJH, Ashcroft FM (1989) ATPsensitive K-channels in HIT T15  $\beta$ -cells studies by patchclamp methods, <sup>86</sup>Rb efflux and glibenclamide binding. Pflügers Arch 415: 47–55

- 42. Corbett JA, Sweetland MA, Lancaster JR, Jr, McDaniel ML (1993) A 1-hour pulse with IL-1beta induces formation of nitric oxide andd inhibits insulin secretion by rat islets of Langerhans: evidence for a tyrosine kinase signaling mechanism. FASEB J 7: 369–374
- Persaud SJ, Jones PM, Wheeler-Jones CPD, Howell SL (1993) Tyrosine kinases and the regulation of insulin secretion. Diabetologia 36 [Suppl 1]: A11 341 (Abstract)
- 44. Henquin JC, Nenquin M (1988) The muscarinic receptor subtype in mouse pancreatic B-cells. FEBS Lett 236: 89–92
- 45. Hughes SJ, Chalk JG, Ashcroft SJH (1989) Effects of secretagogues on cytosolic free Ca<sup>2+</sup> and insulin release at different extracellular Ca<sup>2+</sup> concentrations in the hamster clonal β-cell line HIT-T15. Mol Cell Endocrinol 65: 35–41
- 46. Hughes SJ, Carpinelli A, Niki I, Nicks JL, Ashcroft SJH (1992) Stimulation of insulin release by vasopressin in the clonal beta-cell line, HIT-T15: the role of protein kinase C. J Mol Endocrinol 8: 145–153
- 47. Arkhammar P, Nilsson T, Welsh M, Welsh N, Berggren P-O (1989) Effects of protein kinase C activation on the regulation of the stimulus-secretion coupling in pancreatic betacells. Biochem J 264: 207–215
- Colbran RJ, Schworer CM, Hashimoto Y et al. (1989) Calcium/calmodulin-dependent protein kinase II. Biochem J 258: 313–325
- 49. Bennett MK, Kennedy MB (1987) Deduced primary structure of the beta subunit of brain type II Ca<sup>2+</sup>/calmodulindependent protein kinase determined by molecular cloning. Proc Natl Acad Sci USA 84: 1794–1798
- 50. Hanley RM, Payne ME, Cruzalegui F, Christenson MA, Means AR (1989) Sequence of the cDNA for the alpha subunit of calmodulin kinase II from mouse brain. Nucleic Acids Res 17: 3992–3992
- Tobimatsu T, Fujisawa H (1989) Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs. J Biol Chem 264: 17907–17912
- 52. Huttner WB, Schiebler W, Greengard P, De Camilli P (1983) Synapsin I (protein I), a nerve terminal-specific phosphoprotein: its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol 96: 1374–1388
- Petrucci TC, Morrow JS (1987) Synapsin I: an actin-binding protein under phosphorylation control. J Cell Biol 105: 1355–1363
- 54. Schiebler W, Jahn R, Doucet J-P, Greengard P (1986) Characterisation of synapsin I binding to small synaptic vesicles. J Biol Chem 261: 8383–8390
- 55. Llinás R, McGuinness TL, Leonard CS, Sugimori M, Greengard P (1985) Intraterminal injection of synapsin I or calcium/calmodin-dependent protein kinase II alters neurotransmitter release at the squid giant synapse. Proc Natl Acad Sci 82: 3035–3039
- 56. Nichols RA, Sihra TS, Czernik AJ, Nairn AC, Greengard P (1990) Calcium/calmodulin-dependent protein kinase II increases glutamate and noradrenaline release from synaptosomes. Nature 343: 647–651
- Hughes SJ, Smith H, Ashcroft SJH (1993) Characterization of Ca<sup>2+</sup>/calmodulin-dependent protein kinase in rat pancreatic islets. Biochem J 289: 795–800
- 58. Urquidi V, Ashcroft SJH (1993)  $Ca^{2+}/calmodulin-depen$  $dent protein kinase (CaM kinase) of pancreatic <math>\beta$ -cells exhibits homology with CaM kinase II: immunological and genetic evidence. Diabetologia 36 [Suppl 1]: A113 (Abstract)
- 59. Niki I, Okazaki K, Saitoh M et al. (1993) Presence and possible involvement of Ca/calmodulin-dependent protein kinases in insulin release from the rat pancreatic beta cell. Biochem Biophys Res Commun 191: 255–261

- S.J.H. Ashcroft: Phosphorylation and the beta-cell
- 60. Jones PM, Persaud SJ, Howell SL (1992) Ca<sup>2+</sup>-induced insulin secretion from electrically permeabilized islets: loss of the Ca<sup>2+</sup>-induced secretory response is accompanied by loss of Ca<sup>2+</sup>-induced protein phosphorylation. Biochem J 285: 973–978
- 61. Wenham RM, Landt M, Walters SM, Hidaka H, Easom RA (1992) Inhibition of insulin secretion by KN-62, a specific inhibitor of the multifunctional Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. Biochem Biophys Res Commun 189: 128–133
- 62. Li G, Hidaka H, Wollheim CB (1992) Inhibition of voltagegated Ca<sup>2+</sup> channels and insulin secretion in HIT cells by the Ca<sup>2+</sup>/calmodulin-dependent protein kinase II inhibitor KN-62: comparison with antagonists of calmodulin and L-type Ca<sup>2+</sup> channels. Mol Pharmacol 42: 489–498
- Wenham RM, Landt M, Easom RA (1994) Glucose activates the multifunctional Ca<sup>2+</sup>/calmodulin-dependent protein kinase II in isolated rat pancreatic islets. J Biol Chem 269: 4947–4952
- 64. Ämmälä C, Eliasson L, Bokvist K, Larsson O, Ashcroft FM, Rorsman P (1993) Exocytosis elecited by action potentials and voltage-clamp calcium currents in individual mouse pancreatic B-cells. J Physiol 472: 665–668

- 65. Jones PM, Stutchfield J, Howell SL (1985) Effects of Ca<sup>2+</sup> and a phorbol ester on insulin secretion from islets of Langerhans permeabilised by high-voltage discharge. FEBS Lett 191: 102–106
- 66. Jones PM, Fyles JM, Howell SL (1986) Regulation of insulin secretion by cAMP in rat islets of Langerhans permeabilised by high-voltage discharge. FEBS Letts 205: 205–209
- 67. Wang JL, Corbett JA, Marshall CA, Mc Daniel ML (1993) Glucose-induced insulin secretion from purified beta-cells. A role for modulation of Ca<sup>2+</sup> influx by cAMP- and protein kinase C-dependent signal transduction pathways. J Biol Chem 268: 7785–7791
- 68. Berggren P-O, Arkhammar P, Nilsson T (1989) Activation of protein kinase C assists insulin producing cells in recovery from raised cytoplasmic Ca<sup>2+</sup> by stimulating Ca<sup>2+</sup> efflux. Biochem Biophys Res Commun 165: 416–421
- 69. Basudev H, Jones PM, Persaud SJ, Howell SL (1993) Arachidonic acid-induced insulin secretion from rat islets of Langerhans is not mediated by protein phosphorylation. Mol Cell Endocrinol 91: 193–199
- Ratcliff H, Jones PM (1993) Effects of okadaic acid on insulin secretion from rat islets of Langerhans. Biochim Biophys Acta 1175: 188–191